A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).

NCT07101614 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

125

Enrollment

OTHER

Sponsor class

Conditions

TNBC - Triple-Negative Breast Cancer

Interventions

DRUG: JS004 in combination with toripalimab and chemotherapy
DRUG: Toripalimab and chemotherapy
DRUG: Chemotherapy

Sponsor

Shengjing Hospital